Detalhe da pesquisa
1.
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Cancer Immunol Immunother;
71(4): 865-874, 2022 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34462870
2.
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial.
Int J Med Sci;
18(10): 2245-2250, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33859534
3.
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence.
J Cell Physiol;
235(11): 7900-7910, 2020 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31943171
4.
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
Int J Cancer;
146(7): 1917-1929, 2020 04 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31330065
5.
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.
J Cell Physiol;
234(6): 7708-7717, 2019 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30536609
6.
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
Oncologist;
24(6): e327-e337, 2019 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30796151
7.
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer.
Clin Cancer Res;
29(14): 2714-2724, 2023 07 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37125965
8.
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study.
Front Oncol;
13: 1152123, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37260975
9.
Biosimilar medicines in oncology: single-center experience with biosimilar G-CSF.
Future Oncol;
8(5): 625-30, 2012 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22401144
10.
Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice.
Future Oncol;
8(9): 1193-7, 2012 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23030493
11.
[Pemetrexed monotherapy in previously treated patients with advanced non small cell lung cancer; differences by histology. Our experience]. / Monoterapia con pemetrexed in pazienti pretrattati affetti da carcinoma polmonare non a piccole cellule in fase avanzata: impatto dell'istologia. Nostra esperienza.
Recenti Prog Med;
103(2): 62-5, 2012 Feb.
Artigo
em Italiano
| MEDLINE
| ID: mdl-22430749
12.
Concomitant Mutations G12D and G13D on the Exon 2 of the KRAS Gene: Two Cases of Women with Colon Adenocarcinoma.
Diagnostics (Basel);
11(4)2021 Apr 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33917572
13.
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial.
Sci Rep;
11(1): 13770, 2021 07 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34215766
14.
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting.
Ther Adv Med Oncol;
13: 17588359211059873, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35173816
15.
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
Eur J Cancer;
142: 18-28, 2021 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33212418
16.
Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.
Sci Rep;
10(1): 1918, 2020 Jan 31.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32005869
17.
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.
J Exp Clin Cancer Res;
39(1): 279, 2020 Dec 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33302999
18.
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice.
J Immunother Cancer;
8(2)2020 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33154150
19.
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study.
Oncoimmunology;
9(1): 1710389, 2020.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32002308
20.
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
Clin Lung Cancer;
20(4): 237-247.e1, 2019 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30885550